// App-Quantinova.ai

e12512 : Value of breast cancer molecular subtypes and Ki67 expression for the prediction of efficacy and prognosis of neoadjuvant chemotherapy in a Chinese population.

Researchers

Presenter

  • Jiayu Wang

Principal Investigators

  • Binghe Xu

  • Die Sang

  • Pin Zhang

  • Qing LI

  • Peng Yuan

  • Fei Ma

  • Yang Luo

  • Ying Fan

  • Ruigang Cai

  • Shanshan Chen

  • Qiao LI

Medical Centers

  • Cancer Institute/Hospital Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC), Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

  • Beijing Sanhuan Cancer Hospital, Beijing, China

  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Chinese Academy of Medical Sciences, Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

  • Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Proliferation marker protein Ki-67

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved